EP
CTKB icon

Essential Partners’s Cytek Biosciences CTKB Stock Holding History

Essential Partners’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.78K Sell
1,531
-1,051
-41% -$4.49K ﹤0.01% 1393
2026
Q1 		$11.3K Buy
2,582
+648
+34% +$3.06K ﹤0.01% 1201
2025
Q4 		$9.77K Sell
1,934
-442
-19% -$2.05K ﹤0.01% 1177
2025
Q3 		$8.24K Buy
2,376
+624
+36% +$2.34K ﹤0.01% 1241
2025
Q2 		$5.96K Buy
+1,752
New +$5.84K ﹤0.01% 1005

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Essential Partners's CTKB Position: Q2 2026 in Review

Essential Partners reduced its Cytek Biosciences (CTKB) stake by 41% in Q2 2026, selling an estimated $4.49K and leaving 1,531 shares worth $6.78K. The position accounts for ﹤0.01% of the portfolio, ranked #1393.

Essential Partners first reported a position in CTKB in Q2 2025 and has held it in 5 quarters since. The position peaked at $11.3K in Q1 2026. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Essential Partners held 1,531 shares of Cytek Biosciences worth $6.78K as of Q2 2026.
  • Essential Partners sold 1,051 Cytek Biosciences shares in Q2 2026, an estimated $4.49K.
  • Cytek Biosciences made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1393 holding.
  • Essential Partners first reported a position in Cytek Biosciences in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Cytek Biosciences position peaked at $11.3K in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.